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1970 West Broad Street • Columbus • Ohio 43223
October 1, 2010
The Honorable Ted Strickland
Governor of Ohio
Statehouse
Columbus, OH  43215
 
Dear Governor Strickland: 
The Ohio Prescription Drug Abuse Task Force has completed its work and has developed 20 policy 
recommendations that we believe will curb Ohio’s prescription drug abuse epidemic.
The Task Force’s recommendations preserve a necessary balance between prevention, treatment, law 
enforcement, legislative needs, education needs and policy changes.  These recommendations are the first steps in 
addressing this issue from each of these critical perspectives. We believe that these recommendations address the 
areas of concern identified in Executive Order 2010-4S. 
In just six months, the Task Force has convened 10 full meetings and 15 Work Group meetings, with members 
from a diverse group of professional backgrounds and perspectives, to develop a report and recommendations 
to address Ohio’s complex prescription drug abuse epidemic.  These recommendations reflect hours of discussion 
and debate and represent the consensus of the members of the Task Force. The group had an open and inclusive 
process, giving many individuals and professional organizations the opportunity to comment and have their 
concerns heard.
The members of the Task Force are passionate about this issue. Many of its dedicated professionals have 
committed to continuing to work on combating this epidemic in the future.  Ohio is fortunate to have this 
committed group of leaders as we continue to work at reducing prescription drug abuse and misuse in our state. 
Thank you for your continued commitment to solving this epidemic.  We look forward to working with you in the 
future to implement these recommendations and will continue to fight to protect and improve the well-being of 
Ohio’s residents. 
Sincerely,




Columbus, Ohio 43215  
Governor Strickland,
As Vice Chair of the Ohio Prescription Drug Abuse Task Force (OPDATF), it is my belief that 
all of the members of this group are motivated and eager to continue our work on this issue. In 
the six weeks since the task force was created, we have worked diligently to define the scope of 
the problem and have begun discussion on potential solutions.
The recommendations in this report will serve as the first step towards substantial consumer, 
public health, treatment and law enforcement changes that will address Ohio’s prescription drug 
abuse epidemic.  Over the next few months, we will be working with our colleagues on the task 
force as well as other interested parties in working groups.
While the task force continues meet and develop policy solutions that will address the epidemic 
statewide, the Ohio Department of Health (ODH) is continuing to address the epidemic in the 
hardest hit communities.  We are funding two pilot prevention programs in Montgomery and 
Scioto Counties, through 2013, to develop community driven solutions to this complicated public 
health issue.  In addition, ODH is implementing, “Prescription for Prevention” a comprehensive 
social marketing program in other at risk parts of the state. 
Thank your for your continued support and commitment to addressing this critical public health 
issue.  
Sincerely,
Director Alvin D. Jackson, M.D. 
Ohio Department of Health  
George T. Maier
Assistant Director, Ohio Department of Public Safety
Ohio Prescription Drug Abuse Task Force Chair
Alvin D. Jackson M.D.
Director, Ohio Department of Health
Ohio Prescription Drug Abuse Task Force  Vice Chair
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EXECUTIVE SUMMARY
On April 2, 2010, Governor Ted Strickland signed Executive Order 2010-4S, establishing the 
Ohio Prescription Drug Abuse Task Force (the “Task Force”).  The Task Force was created to 
develop a coordinated and comprehensive approach to Ohio’s prescription drug abuse 
epidemic.  The group was comprised of 33 members with a wide range of professional 
backgrounds and perspectives, including: state and local public health officials, health 
provider board and association representatives, state and local law enforcement, local 
government officials, state agency representatives and legislators.  
The Task Force was charged with meeting regularly to develop and recommend potential 
remedies to the growing misuse and abuse of prescription drugs in Ohio.  Due to the 
urgency of this problem, the Task Force was required to submit an initial progress report to 
the Governor and the leaders of the Ohio General Assembly by May 17, 2010.  The progress 
report included initial recommendations encouraging support for community education 
efforts (i.e.  drug take back programs and social marketing campaigns) and charged the 
Task Force Work Groups to explore and identify potential solutions for the Task Force Final 
Report.
Since the submission of the initial progress report, the Task Force and its Work Groups 
met frequently and have developed 20 recommendations.  In order to ensure the state’s 
approach is both multifaceted and comprehensive, the recommendations address issues 
related to treatment, law enforcement, public health and regulation.  
In accordance with Executive Order 2010-4S, and in support of the Governor’s mission to 
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OhIO’S EpIDEMIC 
From 2000 to 2006, the number of deaths due to unintentional drug overdose in the U.S.  
more than doubled from 11,712, or an average of 32 deaths per day in 2000, to 26,400, or 
an average of 72 deaths per day in 2006.1
Ohio’s death rate has grown faster than the national rate.  In 1999, Ohio’s unintentional 
drug overdose death rate was 2.9 per 100,000 compared to the national rate of 4.0 per 
100,000 (Figure 1).  In 2006, Ohio’s unintentional drug poisoning death rate had risen to 
11.1 per 100,000, compared to the national rate of 8.8 per 100,000.  By 2008, Ohio’s death 
rate rose to almost 13 per 100,000.2
Figure 1.  Ohio3  and U.S.4 Unintentional Drug Overdose Death Rates per 100,000 Population, 1999-2006 (2008 
for Ohio).
18
In Ohio, between 2006 and 2008, the highest average annual death rates due to 
unintentional drug overdose occurred primarily in the state’s southern region (Figure 2).  
Of the counties with the top ten death rates between 2006 and 2008, seven are located in 
this area.
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A wide range of individuals have been found to abuse 
prescription medications.  Although every age group 
has experienced fatalities due to unintentional drug 
overdose, the highest rate of death in 2006 through 
2008 was for 45-54 year-olds.  Although males have a 
1.5 times higher rate of death from opioid poisoning, 
females are the fastest growing at-risk group.7
The epidemic is also having an impact on younger 
Ohioans.  Four out of the top five drugs abused by 
12th graders are prescription or non-prescription 
medications.  In 2007, 26.5 percent of high school students reported using a prescription 
drug without a prescription one or more times in their life.8  The National Center on 
“In one case in particular, a father is 
addicted and has stolen his son’s toys 
and electronics to sell for money to 
buy more drugs.  The boy is wary and 
resentful when his father is in the 
home.”
– Children’s Services Caseworker
Source: Research conducted by Joe Gay, Executive Director, 
Health Recovery Services Inc.
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Addiction and Substance Abuse surveyed teenagers in 2008 and reported that teens were 
able to purchase prescription drugs more easily than beer.9   
In 2007, unintentional drug overdose surpassed motor vehicle crashes and suicide as the 
leading cause of injury death in Ohio for the first time on record (Figure 3).   This trend 
continued in 2008. 
Figure 3. Number of Deaths from Motor Vehicle Traffic10, Suicide and Unintentional Drug Poisonings11  by Year, 
Ohio 1999-2008 
Role of PRescRiPtion Pain Medications
Opioids are chemicals that originate from the poppy flower and its product opium.  They 
are analgesics (pain relievers) that work by binding to specific receptors in the brain, the 
same receptors as natural endorphins, to decrease the perception of pain and increase 
pain tolerance.  They belong to the central nervous system depressant classification 
of drugs, which produce sedation and respiratory depression.  This drug class includes 
prescription pain relievers (e.g., oxycodone, hydrocodone, methadone, fentanyl, codeine, 
morphine, tramadol, etc.) and heroin.  
Physical dependence on opioids develops with long-term use, which can lead to severe 
withdrawal symptoms upon abrupt discontinuation of use.  Due to increasing tolerance 
levels and the feeling of euphoria these drugs can produce, opioids can lead to abuse and 
overdose as individuals must take increasing doses of medication in order to attain the 
same results (e.g., euphoria, pain relief, normalcy, etc.).
“Oh, the pills, that’s huge [among high school students]! They don’t even know 
what they’re taking… and don’t seem to be concerned about it.”
– School counselor, Dayton 
Source: Research conducted by Robert Carlson, Wright State University for the Ohio Substance Abuse Monitoring Network (OSAM).
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When compared to previous drug overdose epidemics, the current prescription drug 
epidemic is responsible for considerably more deaths.  Mortality rates are currently four 
to five times higher than the rates during the “black tar” heroin epidemic in the mid-
1970s and more than three times what they were during the peak years of crack cocaine 
epidemic in the early 1990s (Figure 4).
“I think if all my friends had never tried 
OxyContins, it would have never led to the 
heroin, never.  Everybody [that I know who uses 
heroin] started out with OxyContins.”
– Female, 18, Dayton
Source: Research conducted by Robert Carlson, Wright State University for 
the Ohio Substance Abuse Monitoring Network (OSAM).
Figure 4.  Epidemics of unintentional drug overdoses in Ohio, 1979-2008.12,13,14
Prescription opioids are largely responsible for this alarming increase in drug overdose 
death rates and continue to have a significant impact on this epidemic.  In Ohio in 2008, 
prescription opioids were involved in more unintentional overdoses (37 percent) than 
heroin and cocaine combined (33 percent).15   The opioids most associated with overdose 
are methadone, oxycodone (e.g., OxyContin®), hydrocodone (e.g., Vicodin®) and fentanyl.  
Other opioids such as morphine, meperidine (Demerol®) and hydromorphone (Dilaudid®) 
also play a role.16
Prescription opioids frequently result in accidental overdose in combination with other 
drugs.  In 2008, the majority of unintentional overdose deaths in Ohio that involved a 
prescription opioid, also had at least one of the following listed on the death certificate: 
heroin, cocaine, a hallucinogen, a barbiturate, benzodiazepine, alcohol, or other/
unspecified. 17 Fourteen percent of the deaths 
due to a prescription opioid involved cocaine 
and eight percent involved heroin.18
Individuals who misuse or who are addicted 
to prescription opioids sometimes transition 
to heroin because it is a less expensive, readily 
available alternative that provides a similar 
high.19  A 2002 study by the Ohio Substance 
Abuse Monitoring Network found that  “young, 
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new heroin abusers seeking treatment reported OxyContin abuse prior to becoming 
addicted to heroin.”20  The study also found that “several individuals reported resorting 
to heroin when their OxyContin habits became too expensive or when the drug became 
difficult to obtain.”21
How did tHis BecoMe an ePideMic?
Changing medical and advertising practices have contributed to widespread use of 
prescription drugs across all levels of the population, thereby increasing the scope 
of abuse.  Societal and medical trends that led to this problem include: changes in 
prescribing practices for pain medication, changes in the marketing of medications, 
overmedication, increased use of prescription opioids, self-medication, improper disposal 
of excess medications, and widespread diversion (Figure 5). 
“I was sick one time and couldn’t find any pills [OxyContin]… I was really, really sick. 
And I couldn’t work, and I couldn’t do much, and a friend a mine that was already 
usin’ heroin turned me onto the heroin.  He said that it would take the dope sick 
away.  And from there on, you know, it’s cheaper, it’s quicker….”
– Female, 29, Dayton
Source: Research conducted by Robert Carlson, Wright State University for the Ohio Substance Abuse Monitoring Network (OSAM).
Figure 5.  Contributing Factors to Rising Fatal Drug Death Rates.
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changes in clinical Pain Management
Growing recognition by professionals of the 
under-treatment of pain in the late 1990’s 
prompted needed changes in clinical pain 
management guidelines at the national level, 
as well as changes in Ohio’s law regarding the 
treatment of intractable pain.  As defined in Ohio 
law, “intractable pain” means a “state of pain that is 
determined, after reasonable medical efforts have 
been made to relieve the pain or cure its cause, to have a cause for which no treatment or 
cure is possible or for which none has been found.”22
To address the perception that prescribing adequate amounts of controlled substances 
would result in unnecessary scrutiny by regulatory authorities, Ohio’s Intractable Pain Act 
provided that physicians treating intractable pain are not subject to disciplinary action 
when practicing in accordance with accepted and prevailing standards of care and rules 
adopted by the Medical Board delineating those standards.23  Such fundamental changes 
in the recognition and treatment of pain contributed to increased prescribing and 
concomitant availability of, and exposure to, potent opioid analgesics (pain medications).  
aggressive Marketing of opioids by Pharmaceutical companies
At the same time as these clinical and regulatory changes in the treatment of pain were 
made, the introduction of new, extended-release prescription opioids (e.g., OxyContin®) 
and overly aggressive marketing strategies by pharmaceutical companies to prescribers 
contributed to the growing use of prescription opioids throughout Ohio.24  In 2003, the 
Drug Enforcement Agency (DEA) cited Purdue Pharma’s focus on promoting OxyContin for 
treating a wide range of conditions as one of the reasons the agency considered Purdue’s 
marketing of OxyContin to be aggressive.25  The DEA expressed concern that Purdue 
marketed OxyContin for a wide variety of conditions to physicians who may not have been 
adequately trained in pain management.  Purdue was also cited twice by the Food and 
Drug Administration (FDA) for OxyContin advertisements in medical journals that violated 
the Federal Food, Drug, and Cosmetic Act.26
Growing Use of Prescription opioids
From 1999 to 2007, Ohio’s rate of opioid distribution in grams per 100,000 population 
through retail pharmacies increased 325 percent while the unintentional drug overdose 
death rate increased 305 percent (Figure 6).   These increases represent a nearly one-
to-one correlation, demonstrating that increased exposure to opioids has contributed 
to Ohio’s overdose epidemic.  With the exception of modest decreases in codeine and 
meperidine distribution, nearly all types of prescription opioids experienced dramatic 
increases during this period.27 Hydrocodone combined with acetaminophen (Vicodin®) 
was the most prescribed drug in the U.S. in 2008, according to IMS, an independent 
healthcare information company.28 
“I  was, like, 15 when I broke my ankle, and 
they gave me a prescription of Percs .  .  .  and I 
just haven’t really ever quit since.”
– Male, active user
Source: Research conducted by Robert Carlson, Wright State University 
for the Ohio Substance Abuse Monitoring Network (OSAM).
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direct-to-consumer Marketing of Pharmaceuticals
Beginning in the early 1990’s, there was a significant philosophical shift in the way 
prescription drugs were marketed.  Twenty years ago, direct appeals to consumers by 
prescription drug manufacturers via print and broadcast media was a new phenomenon 
in the health sector.  This approach, known as direct-to-consumer (DTC) marketing, has 
taken an increasingly important position in terms of public awareness of prescription 
drug products.  Surveys have shown that over 90 percent of the public reports seeing 
prescription drug advertisements.34
In 1989, the drug industry collectively spent only $12 million on DTC marketing, compared 
to $2.38 billion in 2001, an increase of almost 200-fold in only 12 years (Figure 7).  A total of 
105 prescription drugs were advertised directly to consumers in 2001.35
Figure 6.  Unintentional Fatal Drug Poisoning Rates29  and Distribution Rates of Prescription Opioids30,31,  in 
Grams per 100,000 Population32  by Year, Ohio, 1997-2007.33
 
Figure 7.  Total Amount Spent in Direct-to-Consumer Advertising of Prescription Drugs, US, 1989-2001.36
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As a result of this change in marketing, the Institute for Safe Medication Practices reports 
78 percent of primary care physicians have been asked for drugs that their patients saw 
advertised on television and 67 percent concede that they sometimes grant patients’ 
requests for medications that are not clinically indicated.   Therefore, many patients may 
be using medications unnecessarily and/or are overmedicated.   
diversion
These and other social trends toward increased prescription drug use have resulted in the 
exposure of a much greater proportion of the public to highly addictive, “legal” substances 
than would be exposed to or likely to experiment with illegal drugs.   Through this 
exposure, which occurs many times for legitimate pain issues, individuals have become 
addicted thus driving the demand for the drugs.  Drug diversion, the unlawful channeling 
of regulated drugs from medical sources to the illicit marketplace, is supplying large 
quantities of controlled substances to fuel addiction.38   
Studies indicate the most common method of diversion is through a family member or a 
friend.  Data from the 2009 National Survey on Drug Use & Health (NSDUH) reveal that 55.3 
percent of  individuals aged 12 or older who engaged in non-medical use of prescription pain 
relievers  obtained the drug they most recently used from “a friend or relative for free.” 39   
Other methods of prescription drug diversion include: 
•	 Utilizing	multiple	physicians	and	pharmacies	to	acquire	controlled	substances	for	




iMPact of tHe ePideMic on law enfoRceMent
In the past decade, the threat to public safety posed by prescription drug abuse has 
increased throughout the Nation.  Data from the 2009 National Prescription Drug Threat 
Assessment show that law enforcement agencies reported the abuse of prescription drugs 
as the fastest growing trend in drug abuse.  In 2004, data showed that 3.1 percent of law 
enforcement agencies reported pharmaceuticals as a threat.  In 2008, this percentage had 
increased to 8.1 percent.40  The availability of prescription drugs has also increased; 48.7 
percent of law enforcement agencies report high availability in 2008 versus 40.8 percent 
in 2004.41 In fact, a greater percentage of law enforcement agencies reported a higher 
availability of prescription drugs nationwide than that of heroin or powder cocaine.  
“The availability is so good because the people want to get rid of ‘em that bad that’s 
why they, we don’t have to really search; it finds us.  People text you, saying, ‘Hey, 
you know, I got this. You want it, you want it?’ People are pushing, tryin’ to push 
‘em away.  I mean, that’s how available they are.”
– Female user
Source: Research conducted by Robert Carlson, Wright State University for the Ohio Substance Abuse Monitoring Network (OSAM).
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Law enforcement agencies are increasingly associating prescription drug abuse with 
violent and property crimes (Figures 8 and 9).  In 2008, 3.5 percent of law enforcement 
agencies reported an association between prescription drugs and violent crime, compared 
to 2.2 percent in 2004.  For property crime, the percentage went from 2.5 percent in 
2004 to 6.0 percent in 2008, while the association between crack cocaine, marijuana, and 
powder cocaine decreased.
Figure 8.  Percentage of Law Enforcement Agencies Reporting an Association Between Drug Type and Violent 
Crime, Nationwide, 2004-2008.42
Figure 9.  Percentage of Law Enforcement Agencies Reporting an Association Between Drug Type and Property 
Crime, Nationwide, 2004-2008.43
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The distribution and use of prescription drugs is regulated by the Federal Controlled 
Substances Act, which classifies controlled substances by schedules according to the 
risk of abuse, the use in accepted medical treatment, and the potential for dependence.  
Despite the strict regulations of these substances, local law enforcement agencies are 
faced with increasing diversion from legitimate sources for illicit purposes, including: 
doctor shopping, forged prescriptions, falsified pharmacy records, and employees who 
steal from their place of employment.  This on-going diversion of prescription narcotics 
creates a lucrative marketplace.  For example, a bottle of 100 OxyContin® 80 mg tablets, 
which normally costs $700-800 at the pharmacy, has a street value of $7,000-8,000.44   
A growing problem for law enforcement throughout 
the state, particularly in southern Ohio, is diversion 
through clinics that prescribe and/or dispense 
powerful narcotics inappropriately or for non-
medical reasons.  These clinics are often referred to 
as “pill mills.”  Pill mills are sometimes disguised as 
independent pain-management centers.  They often 







medication within the clinic; 
•	 Irregular	hours	of	operation;
•	 Presence	of	security	guards;	and
•	 Long	lines	of	people	waiting	outside	of	the	building.45   
These facilities usually open and shut down quickly in order to evade law enforcement.  
Authorities believe that as many as eight pill mills could be operating in Scioto County 
alone, which has a population of 76,000 residents.46 
One of the most notorious owners of a pill mill was Dr. John Lilly.  Dr. Lilly was an 
orthopedic surgeon in Portsmouth, Ohio.  He was arrested in March of 2000 for operating 
one of the largest narcotics operations in the Midwest.  About the time that Dr. Lilly started 
his pain clinic, local police noticed that drug-related crimes in Portsmouth started to trend 
upward.  Burglaries increased 20 percent compared to the previous year and, for a period 
of about three months, police records showed homes and pharmacies were being broken 
into and robbed of prescription drugs almost daily.47 
After his arrest, police found an x-ray machine that did not work and beer cans on the 
waiting room floor.  According to the Portsmouth Chief of Police, Dr. Lilly would perform 
little or no physical examination after collecting $200 cash.  He would merely elicit a 
complaint from a patient, note the complaint as “intractable pain”, and give the patient 
“I could get Roxicet for $4 a piece; Percocet 
5s, $4 a piece; Perc 10s $6 a piece; Perc 
[immediate release oxycodone] 15s 
are, like, $10 a piece; and then Perc 
[immediate release oxycodone] 30s, those 
go for $20.  And the Oxys, those go for a 
dollar a milligram, and Vicodin 5, [$]2; 
Vicodin 10, [$]4; and then, um, Valium 5s 
are a dollar; and then the Valium 10s go 
to [$]2; and the V cuts go to [$]5.”
– Active user, Columbus
Source: Research conducted by Robert Carlson, Wright State 
University for the Ohio Substance Abuse Monitoring Network 
(OSAM).
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a prescription.  He charged $10 for each narcotic pill and an additional $10 for each 
OxyContin.48  Over a six-month period, Dr. Lilly wrote more than 4,000 prescriptions, most 
of which were for pain medications.  An investigation revealed that people came from as 
far as Texas to obtain prescriptions.49  Police also found almost half a million dollars in cash 
in his basement and almost an additional $100,000 in a separate apartment he kept next 
to his practice.   
The investigation into Dr. Lilly’s practice took almost four months and required the 
assistance of four full-time officers and three Ohio Bureau of Criminal Identification and 
Investigation (BCI) agents.50  Investigations like these require a great deal of time and 
resources and can present challenges to small law enforcement agencies with limited 
funding.  
iMPact of tHe ePideMic on tReatMent
Prescription drugs are the second most abused category of drugs in the United States, 
following marijuana.51  In 2008, an estimated 23.1 million people needed treatment for 
a substance use disorder in the U.S.52  Between 1998 and 2008, treatment admissions for 
prescription painkillers increased 460 percent nationwide.  In the past decade, admissions 
for non-heroin opioid substance abuse treatment have increased more than 300 percent 
in Ohio (Figure 10).
Figure 10.  Number of substance abuse treatment admissions for non-heroin opioids by year, Ohio, 1993-2008 53
There are approximately one million individuals in Ohio who need substance abuse 
prevention or treatment services.  Only one in ten of the people in the state who need 
these services receive them through the publicly funded system.54   In State Fiscal Year 
(SFY) 2009, 14,585 clients had a diagnosis of opiate abuse or dependence, equaling 14 
percent of the total 103,469 clients within the publicly funded alcohol or other drug (AoD) 
system of care.55  
The state of Ohio spent $5.4 billion, or roughly $468 per Ohio resident on untreated 
addiction related costs in 2005.56  Untreated addiction increased state spending in areas 
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such as child welfare, adult corrections, and juvenile justice.  Across the nation, these 
related costs have significantly increased causing the burden of substance abuse to 
surpass the amount states spend on education.57 
iMPact of tHe ePideMic on PUBlic HealtH
Prescription opioid misuse, abuse and overdose have an enormous impact on the health 
of Ohio residents.  On average, from 2006 to 2008, approximately four people died each 
day in Ohio due to drug-related overdose.58  In response to the devastating effects of 
this problem in Scioto County, including a rise in overdose deaths, an increase in those 
seeking treatment for opioid addiction, and a rise in crime, the city and county health 
commissioners declared a public health emergency in January 2010.59 
 
The health and safety of individuals and communities are at risk, as the consequences 
of this problem go far beyond the individual who is misusing or addicted to these drugs 
and reach well into the community.  Some of the repercussions for individuals include job 
loss, loss of custody of children, physical and mental health problems, homelessness, and 
incarceration.  This results in instability in communities often already in economic crisis 
and contributes to increased demand on many community services such as hospitals, 
medical professionals, courts, children’s services, treatment centers and law enforcement.  
For example, according to data gathered by the Ohio Department of Health (ODH) from 
Ohio hospitals, more than nine out of ten (95.7 percent) poisoning hospitalizations in Ohio 
are due to drugs.  Further, hospital emergency department visits for “drug overdose” or 
“symptoms of drug overdose” as the chief complaint on admission rose from 40 to 70 per 
day in August 2007, to 50 to 80 per day in July 2008.  There were never less than 40 visits 
per day during this time period.
In addition to the personal costs experienced, the annual costs of unintentional drug 
overdose are also shocking; $3.5 billion in fatal costs (including medical, work loss, and 
quality of life loss) and $31.9 billion in non-fatal, hospital admitted costs (Figure 11). 
In 2003, Fairfield County spent $350,000 incarcerating opiate addicts.  By 2008, 
the cost of incarcerating opiate addicts had increased to $2.5 million.
Source: The Fairfield County Opiate Task Force, Presentation to the Ohio Prescription Drug Abuse Task Force, August 18, 2010.
Figure 11.  Estimated Average Annual Costs of Unintentional Drug Overdose in Ohio60
type of costs fatal costs non-fatal, hospital admitted costs
Medical $4.9 million $19.1 million
Work Loss $1.2 billion $5.2 million
Quality of Life $2.2 billion $7.6 million
Total $3.5 billion $31.9 million
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As one method of combating the problem of 
prescription opioid abuse, local public health 
departments, prevention educators, alcohol and 
drug treatment agencies, health care providers, law 
enforcement agencies and many other partners in 
communities across Ohio have come together to 
form coalitions to raise public awareness, promote 
community action and implement educational 
programs about the dangers and devastating 
effects of prescription opioid abuse.  The following 
are two examples of such efforts.
In Scioto County, the Scioto County Rx Drug Action Team was formed in January 2010, 
in response “to the epidemic of prescription drug abuse, misuse, overdose, consequent 
death and disease incidence and social disruption.”61  The Action Team spawned several 
specialized groups, including a large citizen’s support group called SOLACE.
SOLACE stands for “Surviving Our Losses and Continuing Everyday” and is a support group 
for family members who have lost a loved one to a drug related death.  The group, which 
meets in Portsmouth, takes an active role in raising awareness and is working to prevent 
future drug-related deaths.  SOLACE is open to anybody who is passionate about stopping 
drug abuse in their community, anybody in a recovery program, or any person who has a 
loved one who is addicted and needs someone who understands.
In July 2010, the group held a “Rockin’ for Recovery Project” event on the town square in 
Portsmouth and unveiled the “Be the Wall Against Drugs” community awareness campaign 
featuring a memorial wall with photographs of people lost to drugs.  The wall remains on 
prominent display, in a department storefront window, in downtown Portsmouth.  This 
project puts a face to the problem and reminds passersby that everyone must “be the wall” 
for the community so that no more Ohioans are sacrificed to this epidemic.
SOLACE members also volunteer to do drug prevention education with youth, participate 
in public awareness and education events, and provide support to families who are 
experiencing crisis related to a family member’s drug use, addiction, or death.  The group 
also maintains a Facebook page that serves as a source to link interested parties with 
services.62 
Another community outreach effort is taking place in Jackson County, which also has 
one of the highest rates of unintentional drug overdose deaths.63  A group of concerned 
citizens came together and formed the Launch Youth Leadership Team (LYLT) to engage 
young people in making a difference in their community.  The LYLT identified prescription 
drug misuse and abuse by teens as a problem in their community, they educated 
themselves about this issue, and they took action.  
The LYLT teens are working with their schools to present educational programs with 
a peer-to-peer approach to raise awareness with other students.  They agreed on a 
“Protect Your Pills” theme and developed a brochure about proper storage and disposal 
of prescription drugs.  The Launch Team and adult community volunteers delivered 
13.9 million doses of hydrocodone and 
oxycodone were legally dispensed to the 
residents of Fairfield, Athens, Hocking and 
Perry counties in 2009.  This is equal to 52 
pills for every man, woman and child in 
these counties.
Source: The Fairfield County Opiate Task Force, Presentation to the 
Ohio Prescription Drug Abuse Task Force, August 18, 2010.
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12,000 flyers to pharmacies throughout Jackson County in February 2010.  The flyers were 
handed out with every prescription purchased through mid-March 2010 and highlighted 
the importance of properly monitoring, securing and disposing of over-the-counter and 
prescription drugs.  This is an on-going biannual effort and is an example of a coordinated 
community response with youth and adults working together in partnership with local 
businesses.
 
iMPact of tHe ePideMic on HealtHcaRe PRofessionals
Medical providers are also impacted by this epidemic.  Patients who suffer from intractable 
pain may need medical care that includes prescription opioids.  Prescription opioids, when 
taken exactly as prescribed, can assist individuals living in pain by improving their quality 
of life.   However, when abused or taken improperly, these drugs can produce serious 
adverse health effects, including addiction and overdose.64 
Most doctors will treat a significant number of patients with pain problems or substance 
abuse issues throughout their careers.65  However, these issues are only a small part of 
most physicians’ medical training.  In fact, many doctors may only receive a few hours of 
education on the use and potential consequences of opioids during their time in medical 
school.66  
As a result, medical providers may be unprepared to deal with the complexity of issues 
arising from the treatment of chronic pain and/or prescription drug abuse.  Some 
providers overprescribe combinations of medications to treat pain while others choose 
not to work with patients who have ongoing pain issues because of fear of prescription 
drug abuse, liability, or personal or professional biases.67  Doctors can face criticism if 
they have high numbers of pain-related cases or prescribe significant amounts of pain 
medications.68  Additionally, doctors are often confronted with the difficult position 
of judging if certain patients are deceiving them to obtain prescriptions to feed their 
addictions or sell to others, or if they are legitimately in need of these medications to treat 
their pain.  
Pharmacists have also been negatively impacted by Ohio’s prescription drug abuse 
problem.  Over the past few years there has been a growing trend of pharmacy crimes 
including robbery and burglary.  A 2005 study by The Center on Addiction and Substance 
Abuse at Columbia University revealed that 28.9 percent of pharmacists responding had 
experienced robbery or theft within the previous five years.69  
Pharmacy robbery has grave implications; the robber may be armed, may have 
accomplices, and may even jump over the counter to take what he or she wants.  
Pharmacy robberies frequently target brand name controlled substances, as Vicodin®, 
Percocet®, OxyContin®, and Xanax®.   The survey also indicated that 20.9 percent of 
pharmacies no longer stocked certain medications, such as OxyContin® and Percocet,® in 
order to protect themselves from pharmacy robbery.70 
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 LAw ENFORCEMENT RECOMMENDATIONS 
The Task Force Law Enforcement Work Group was charged with developing 
recommendations to assist law enforcement in combating the prescription drug abuse 
epidemic.  The Work Group was chaired by Matthew Kanai of the Ohio Attorney General’s 
Office, and Lili C.  Reitz, Executive Director of the Ohio State Dental Board served as the 
vice chair.  The Group consisted of members representing federal, state and local law 
enforcement agencies, professional healthcare organizations, state licensing boards, 
prosecutors, county Drug Task Forces, and state agencies.  
The Law Enforcement Work Group was charged with the following areas of responsibility:
•	 Explore	mechanisms	to	increase	multi-jurisdictional	collaboration	within	the	criminal	
justice and law enforcement community to investigate and enforce prescription drug 
abuse cases.  
•	 Explore	funding	opportunities	for	criminal	justice	and	law	enforcement.
•	 Identify	opportunities	and	strategies	for	greater	local,	state	and	federal	collaboration	
on issues regarding prescription drug abuse cases.  
•	 Identify	other	strategies	to	strengthen	the	role	of	law	enforcement	in	dealing	with	the	
issue.
The Work Group met on July 14, August 11, and September 20, 2010.  The Group came to 
consensus on four recommendations, which were presented to the Task Force for further 
consideration.  Final recommendations presented herein were determined after discussion 
with the Task Force and through a consensus-based decision-making process.  
iMPleMent standaRds foR Pain ManaGeMent clinics
The majority of pain clinics and physician offices in Ohio contribute to the health and 
safety of Ohioans by legitimately caring for persons with acute and chronic pain issues.  
However, so-called “pill mills” cloak themselves under the guise of pain clinics and furnish 
controlled substances in an irresponsible manner.  Current Ohio law makes it difficult 
to address situations in which members of a trusted profession abuse their position by 
shielding illegal activity within their practice area.  
Ohio House Bill 547 (H.B. 547), as recently introduced in the General Assembly, enhances 
the enforcement capabilities of the law enforcement and regulatory agencies by 
identifying and focusing on rogue pain clinics that operate outside accepted and 
prevailing standards of care.  This legislation utilizes an existing licensing mechanism 
at the Ohio Board of Pharmacy (BoP) to address outlier pain clinics that should be 
distinguished from legitimate pain practices.  The licensure process will enhance 
the tools that regulatory bodies have in pursuing illegitimate clinics by requiring 
physician ownership, background checks and prohibiting ownership interests that 
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have a felony record.  In addition, one of the 
benefits of authorizing the BoP to license pain 
management facilities is that the agency would 
have jurisdiction to deny licensing to rogue 
clinics and take disciplinary action against those 
clinics that practice outside the law and accepted 
operational standards.  As a result, the burden on 
law enforcement to monitor these clinics will be 
reduced.  
H.B. 547 also provides the State Medical Board 
with greater authority to develop standards of 
care for physicians who own or practice in a pain 
management clinic.  The legislation directs the 
Medical Board to promulgate rules to: “ensure 
that any person employed by the facility complies 
with the requirements for the operation of a 
pain management clinic;” to establish “standards 
for the operation of a pain management clinic 
by a physician;” and to “establish standards and 
procedures to be followed by physicians regarding 
the review of patient information available through 
the drug database.”   Establishing and updating 
standards of care and procedures for prescribers 
and clinics through the rule making process 
would clearly differentiate legitimate clinics from 
criminal operations thereby allowing regulators 
and law enforcement to focus activities on unlawful 
facilities.   
By giving regulatory boards the proper tools and 
the authority to use them in enforcing the laws, 
H.B. 547 reduces the burden on criminal authorities 
to proceed with the difficult task of criminal 
proceedings.  Currently, criminal actions initiated 
in the courts require professional licensing boards 
to wait for a decision in the criminal matter before 
taking further action based on a conviction.  The 
legislation sets out to strengthen the ability of the 
State Medical and Pharmacy Boards to summarily 
suspend (to suspend without a prior hearing) the 
license of a facility or a practitioner if there is clear 
and convincing evidence of immediate and serious 
harm to the public.  
The General Assembly should consider whether 
the definition of a “pain management clinic” in 
H.B.  547 is sufficient and will be effective for these 
John*
John lives in one of the communities in Ohio 
hardest hit by opioid use.  John made good grades 
and was active in sports and school activities. His 
first exposure to opioids was a prescription at age 
19 after breaking his ankle. He continued to take 
opioids on his own after the prescription was 
discontinued, first obtaining pills from a family 
member’s prescription and then buying them “on 
the street.” 
He stopped using for a year and went away to 
college. Upon returning to the community, he 
resumed his use and it was soon out of control. 
John said that when he left opioids were hard to 
find but when he got back they were everywhere.
John once wrote down the names of everyone he 
knew who sold pills. There were 60 people on the 
list, all from his small community. 
John supported his habit by stealing, which was 
very much contrary to his values. He became 
depressed, suicidal, and attempted suicide 
several times. Withdrawal he describes as 
“Terrible. I’ve always compared it to being held 
under water. All you want is a breath of air. All it 
takes is $30 to feel OK.”
After attempting suicide, being in a psychiatric 
hospital, and facing jail, he entered treatment. 
After struggling to remain abstinent while on a 
waiting list, he has stabilized on Suboxone and 
counseling and is making good progress.
John said, “I graduated in a class of 67 people; 
within 10 years 15 were dead from drugs.”
*Name has been changed; individual did not wish to 
be named. Source: Research conducted by Joe Gay, 
Executive Director, Health Recovery Services Inc.
35
purposes.  Under the proposed law, a facility is a pain management clinic if its “primary” 
practice is the treatment of pain.  This means treatment specific to pain, as opposed to the 
underlying condition that causes pain.  Accordingly, a doctor could treat both and avoid 
being classified as a pain management clinic.  This could create an exploitable loophole 
that should be addressed in the legislative process.  
The General Assembly should also consider requiring other professional licensing boards 
to develop rules specifying when pharmacists and other authorized prescribers are 
required to review patient data in the Ohio Automated Rx Reporting System (OARRS), 
which is the state’s prescription monitoring program.  H.B. 547 requires only the Medical 
Board to adopt rules specifying when a physician is required to review information in 
OARRS.  By standardizing requirements in this area, the state is encouraging greater 
transparency and accountability to the public and practitioners.  
Overall, the legislation seeks to enhance opportunities for greater collaboration between 
the State Medical and Pharmacy Boards. While these agencies are critical to successfully 
addressing the abuses identified by the Task Force, the various provisions in H.B. 547 
should help foster greater collaboration and effectiveness of the entire law enforcement 
community.
Therefore, the Task Force supports passage of H.B. 547 or a successor bill that addresses 
the same issues - in particular, the provisions allowing for summary suspension, additional 
regulatory authority for the Medical Board and BoP, licensure of pain management 
clinics, and enhancing the use of OARRS - while strengthening the definition of a pain 
management clinic to avoid any potential loopholes.   The General Assembly should 
partner with professional licensing boards, healthcare provider organizations, and state 
and local law enforcement agencies to implement this recommendation. 
leGislatiVe RefoRM to incRease tHe effectiVeness of law enfoRceMent 
in inVestiGatinG and PRosecUtinG PRescRiPtion dRUG aBUse cases
The Task Force recommends that the General Assembly propose and support additional 
legislative efforts to increase the capacity of law enforcement to be more aggressive and 
more effective in its ability to investigate and prosecute prescription drug abuse cases.
These provisions may include, but are not limited to:
•	 Limiting	the	unit	dosage	of	Schedules	II-IV	drugs	an	individual	can	possess	for	a	
given time period.  The unit dosage amount and time period should be tailored so 
that only the most extreme legitimate cases would be included, leaving the majority 
of legitimate patients unaffected.  The State BoP, in consultation with the State 
Medical Board, should be given the authority to adopt rules regulating what would 
be considered a maximum quantity of prescribed opiates and other controlled 
substances to be possessed by an individual at one time. Possession of greater than 
the unit dosage amount by a specified amount creates a rebuttable presumption 
(one that is taken to be true unless someone comes forward to contest it and prove 
otherwise) of criminal possession.  The rebuttable presumption of criminal possession 
would also apply to pills or prescriptions that come across state lines into Ohio.  
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•	 Lowering	the	bulk	amount	of	drugs	for	Schedule	III	and	IV	and	increasing	the	criminal	
penalty for possession of bulk amounts to better enable law enforcement to pursue 
felony possession charges.
•	 Requiring	those	in	possession	of	drugs	that	are	not	in	their	original	containers	to	
prove within a specified period of time that the drugs were acquired through a lawful 
prescription.  This requirement would not create an additional criminal offense for 
failure to comply, nor would it prevent an officer who otherwise has probable cause 
that a crime has been committed to arrest or confiscate such drugs.  
•	 Enhancing	and	strengthening	current	reporting	requirements	of	licensed	healthcare	
professionals (i.e.  physicians, dentists, nurses, pharmacists, veterinarians) who 
reasonably suspect other healthcare providers are committing prescription drug 
violations, including the requirement of inter-disciplinary reporting.  
•	 Implementing	an	efficient	reporting	process	for	physicians	and	other	healthcare	
professionals wanting to report doctor shopping or abuse to law enforcement.  
An efficient reporting process would emphasize the vital role that healthcare 
professionals can play in cooperation with local law enforcement.  
•	 Requiring	all	licensees	permitted	to	prescribe	prescription	narcotics	to	use	a	
standardized, tamper resistant prescription pad or standardized electronic 
prescribing.
•	 Increasing	fines	for	prescription	drug	abuse	convictions.71  
•	 Developing	rules	and	utilizing	systems	for	sharing	interstate	records	regarding	
pharmaceutical investigative information (i.e.  history, criminal activity, etc.) with 
other states.
Stronger legislation creates clear standards that place greater control on enterprises that 
predominantly involve drugs that are prone to abuse.  These recommendations require 
leadership by the General Assembly in collaboration with law enforcement agencies across 
the state, healthcare provider organizations and professional licensing boards.  
PRoMote cooPeRation, coMMUnication, edUcation, and tRaininG aMonG 
law enfoRceMent aGencies
Laws and rules pertaining to the enforcement of criminal activity relating to prescription 
drugs are underutilized.  Traditionally, there has been hesitancy about encroachment and 
disagreement about methods of investigation and prosecution.  The lack of knowledge 
by law enforcement of existing laws and rules (i.e. such as in the area of drug trafficking 
and illegal processing of drug documents) may also result in ineffective application of 
those laws to licensed individuals committing crimes related thereto.  There is also a lack 
of strong cooperative working relationships among various levels of law enforcement and 
knowledge about existing resources and tools for enforcement.
The Task Force recommends that law enforcement work to promote cooperation and 
communication among federal, state and local law enforcement agencies.  By developing 
working relationships and fostering collaboration at all levels of law enforcement, agencies 
can maximize existing resources to address criminal activities relating to prescription drug 
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abuse.  In addition, developing improved communication will allow law enforcement 
officials to clarify jurisdictional issues to prevent overlapping investigations.  
In order to promote greater cooperation and education, the Task Force recommends 
that law enforcement agencies hold a summit to identify resources, tools, and training 
available to combat criminal activity involving prescription narcotics.  The summit should 
address the traditional hesitancy about encroachment, best-practices regarding methods 
of investigation and prosecution, existing laws, and resources available to foster improved 
linkages among all levels of law enforcement.  
The necessary partners for this recommendation include local, state and federal law 
enforcement agencies involved in the investigation and prosecution of prescription drug 
cases.  The Task Force recommends including agencies that are not directly linked to 
drug diversion enforcement (such as the IRS as it focuses on financial and organizational 
investigations), as well as regulatory agencies interested in productive law enforcement 
investigations.  Cooperation with the Ohio Peace Officer Training Academy (OPOTA) and 
other similar education sponsors is also needed.  The Governor and/or Attorney General 
of Ohio should take a leadership role in implementing this recommendation.  The U.S. 
Attorney’s Office indicated it may have training funds available to assist in carrying out this 
recommendation.  
condUct coMPReHensiVe ReView of fUndinG initiatiVes foR law 
enfoRceMent issUes Related to PRescRiPtion dRUG aBUse
The Task Force recommends that the Governor designate the appropriate state agency to 
catalogue available resources to assist law enforcement in combating prescription drug 
abuse and develop a coherent statewide plan on distribution.  Additional resources are 
required to address the funding needs of law enforcement such as direct sponsorship of 
prescription drug-related investigations and prosecutions, enhancement of the existing 
OARRS database, and community education and outreach.  A comprehensive review 
should not preempt a local agency from seeking funds, but should help provide statewide 
coordination.  
A review of existing funding should include but are not limited to the following:
•	 Resources	available	for	investigations,	such	as	task	force	seed	money	from	the	
Organized Crime Investigations Commission, the Ohio Department of Public Safety’s 
Office of Criminal Justice Services, and other state and federal sources.
•	 Forfeiture	funding.	
•	 Grants	from	the	National	Association	of	Drug	Diversion	Investigators.		
Given the complexity of identifying all available sources, it is recommended that the 
Governor designate an appropriate agency to begin compiling the necessary information 
immediately.  Critical partners include the Ohio General Assembly, the Ohio Department 
of Public Safety (DPS), the Ohio Attorney General’s office, and federal grant-administering 
agencies.  
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 TREATMENT RECOMMENDATIONS 
The Treatment Work Group was charged with developing recommendations to improve 
the treatment outcomes of those who currently abuse prescription narcotics. The Work 
Group was chaired by Ed Hughes, who represents the Ohio Council of Behavioral Health 
& Family Services Providers, and co-chaired by Dr. Cleanne Cass of the Ohio Osteopathic 
Association. The group’s membership included more than 40 individuals from a variety 
of professional backgrounds including treatment and prevention service professionals, 
physicians, pharmacists, regulatory entities, professional healthcare organizations and 
educators.   ODADAS was the lead agency for the group and a facilitator from the Ohio 
Department of Administrative Services (DAS) was used during each of the meetings.
The Treatment Work Group was charged with the following tasks: 
•	 Identify	state	medical/healthcare	associations	to	request	they	make	a	commitment	
to address the prescription drug abuse problem in upcoming meetings, conferences, 
courses and newsletters. 
•	 Identify	mechanisms	to	ensure	that	individuals	with	chronic	pain	are	given	
appropriate treatment and healthcare providers are not dissuaded from including 
pain management in their practice. 
•	 Examine	screening/referral	and	treatment	options	available	in	Ohio	to	individuals	
addicted to prescription drugs. 
•	 Identify	and	promote	to	medical	professional	associations	educational	programs	for	
physicians and other prescribers that address the issue. 
•	 Work	with	medical	associations	to	identify	and	implement	model	prescribing	
guidelines for all prescribers.
•	 Initiate	and	support	efforts	to	increase	the	capacity	for	treatment	for	opioid	addiction	
including medication assisted treatment.  
The Work Group met for more than 12 hours in a series of three meetings in the months of 
July and August 2010.  The group worked on converting general ideas and concerns into five 
specific recommendations. Final recommendations presented herein were determined after 
discussion with the Task Force and through a consensus-based decision-making process.  
enHance ResoURces aVailaBle witHin tHe alcoHol and otHeR dRUG 
addiction sYsteM of caRe foR diRect client seRVices
In Ohio, it is estimated that there are 916,000 people who need treatment.  Only 1 in 10 of 
those individuals received treatment and recovery services through the publicly funded 
system.72  In SFY 2009, the Ohio Department of Alcohol and Drug Addiction Services 
(ODADAS) provided treatment and recovery services to more than 100,000 individuals.73   
However, only about 30 percent of the people in the AoD system of care in Ohio have 
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Medicaid to cover some of their costs.74 
Treatment is essential to decreasing the criminal 
and delinquent behavior tied to drug use that 
disrupts family, neighborhood, and community 
life in fundamental and long-lasting ways.75  A 
2010 report, released by the Substance Abuse and 
Mental Health Services Administration (SAMHSA), 
states that 73 percent of those in treatment report 
a greater ability to function at home, work, or 
school.76  In addition, 68 percent of women who 
stayed in comprehensive treatment longer than 
three months were able to remain alcohol and drug 
free, compared with 48 percent who left treatment 
within the first three months and did not remain 
alcohol and drug free.77  
The Task Force recommends that additional funding 
opportunities for the AoD system at the Federal 
level be explored.  An investment in treatment is 
an investment in savings. For most clients in Ohio, 
the average annualized cost per client for treatment 
is approximately $1,600, as compared to the cost 
of incarceration per person, which is $25,000 
annually.78  Funding sources should also be explored 
to encourage the increased use of programs 
for addicted individuals such as drug courts, 
rehabilitation centers, and therapeutic communities 
to provide addiction treatment options rather than 
incarceration.  
ODADAS should partner with the Ohio Council of 
Behavioral Health and Family Services Providers, 
Ohio Association of County Behavioral Health 
Authorities, The Ohio Alliance of Recovery 
Providers, healthcare provider organizations, and 
professional licensing boards to implement this 
recommendation.  Success would be measured by 
the increase in people receiving treatment services 
for opioid addiction and the number of initiatives 
pursued to diversify resources to the AoD field.
adoPt a statewide standaRdiZed 
scReeninG and RefeRRal tool
Primary care centers, hospital emergency rooms, 
trauma centers, and other community settings 
have limited opportunities for early intervention 
Kim
Kim, now age 27, had a friend with an opioid 
prescription and asked to try one.  Liking it, she used 
her friend’s prescription then started buying pills 
“on the street.” Shifting to more potent preparations 
and larger numbers of pills, the resulting dosages 
rapidly increased and she could barely sustain the 
habit.  She commented: “I heard there was this 
little bag of stuff for $40 that would do more than 
the pills did.” That was heroin.  She started taking it 
orally but her tolerance increased rapidly.  
She had a friend who was already using a needle. 
“I forced him to shoot me up.  He begged me not to 
do it.” As with pills, her tolerance rapidly increased 
until her habit was at $400 to $600 per day.  She 
said that she sustained it by selling drugs.
Children’s Services took custody of her older 
daughter.  Another daughter was born addicted 
to heroin.  The daughter spent four months in 
the hospital treated with methadone to prevent 
withdrawal.  Children’s Services transferred custody 
of the children to Kim’s parents.  “I really didn’t care. 
I wasn’t bonded to her,” Kim said with regret.
After the birth of her second daughter, Kim began 
treatment.  She has had her struggles with relapse. 
She has now entered a program that offers strong 
counseling support with Suboxone and is doing 
well.  She said the Suboxone “has helped 110 
percent with staying clean.” 
She is now working towards regaining custody 
of her children but admits it is a slow process, in 
terms of connecting with the children, regaining 
the trust of her parents, and proving herself 
reliable to Children’s Services.
Source: Research conducted by Joe Gay, Executive 
Director, Health Recovery Services Inc.
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with at-risk substance users before more severe consequences occur.  In fact, of the 23 
million Americans who are addicted to drugs and alcohol, 95 percent of those who needed 
treatment did not receive any and were unaware that there were programs in place to help 
them recognize substance abuse problems.79   
Ohio lacks an integrated and coordinated system of screening and treatment components. 
A system of services should link a community’s specialized treatment programs with 
a network of early intervention and referral activities conducted in medical and social 
service settings, including an effective referral mechanism between the AoD field, 
physicians, and hospitals.  
The Task Force recommends examining the statewide implementation of the Screening, 
Brief Intervention, and Referral to Treatment (SBIRT) program.  Interventions such as 
SBIRT decrease the frequency and severity of drug and alcohol use, reduce the risk 
of trauma, and increase the percentage of patients who enter specialized substance 
abuse treatment.80  The SBIRT model involves the implementation of a system within 
the community and medical settings which screens for and identifies individuals with 
substance use related problems, including physician offices, hospitals, education 
institutions, and mental health centers.  The system would then allow for brief intervention 
or treatment within the community setting and refers those identified as needing more 
extensive services than can be provided in the community setting, to a specialist for 
assessment, diagnosis, and appropriate treatment.81
SBIRT is easy to implement and requires minimal financial support.  It is a federally funded 
program that has already been implemented in 17 states and as of February 2009, 658,000 
patients have been screened with the SBIRT model.82  If the state were to implement 
the program, for every one dollar spent on SBIRT, almost a 4 dollar savings would result 
in health care costs, which could amount to almost a $2 billion in hospital savings each 
year.83  Federal funding opportunities for the SBIRT program should be explored and an 
SBIRT pilot program could be introduced to study the efficacy of statewide program.
ODADAS and the Ohio Department of Job and Family Services (ODJFS) should partner 
with the Ohio Council of Behavioral Health and Family Services Providers, Ohio Association 
of County Behavioral Health Authorities, the Ohio Alliance of Recovery Providers, 
healthcare provider organizations, and professional licensing boards to implement this 
recommendation.  Success of this recommendation would be measured by an increase in 
number of persons accessing the system who are addicted to prescription opioids. 
incRease edUcation of PReVention, inteRVention, tReatMent, and 
RecoVeRY sUPPoRt seRVices aMonG HealtHcaRe PRofessionals
The costs and consequences of opioid addiction are staggering.  If substance abuse and 
addiction were its own state budget category, it would rank second just behind spending 
on elementary and secondary education.84  However, for every dollar spent on substance 
abuse, 95.6 cents went to the societal consequences of addiction and only 1.9 cents on 
prevention and treatment, 0.4 cents on research, 1.4 cents on taxation or regulation and 
0.7 cents on interdiction.85
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Most physicians will treat a significant number of patients with substance abuse issues 
throughout their careers.  Substance use disorders affect 45 percent of patients who 
present for medical care but are routinely unrecognized by healthcare providers.86  These 
issues represent only a small part of most physicians’ medical training.  In fact, many 
doctors may only receive a few hours of education on substance abuse during their 
time in medical school.87  A recent study published by The National Center of Addiction 
and Substance Abuse at Columbia University found that only 40 percent of surveyed 
physicians received any training in medical school in identifying prescription drug abuse 
and addiction.88
Physicians and other healthcare providers can play a key role in facilitating the screening, 
diagnosis and treatment of patients with substance use disorders.  However, lack of 
knowledge about the disease of addiction, clinical screening techniques and referral 
resources increases clinician reluctance to evaluate patients for substance use disorders.  
People suffering from addiction are still heavily stigmatized. Physicians are not immune 
from negative attitudes about substance abuse.89  There is benefit in the education of 
physicians about the disease of addiction as a disease of the brain and comparable to 
other chronic medical conditions such as diabetes, asthma, or high blood pressure which 
also need ongoing monitoring and treatment.  
Further, increasing initial and continuing education of prescription drug abuse issues 
across a variety of professional healthcare disciplines will lead to increased use of 
structured screening tools and referrals into the AoD treatment services system. This 
action will ultimately reduce the number of deaths associated with prescription drug 
abuse and the costs of these disorders to individuals, families, and society. 
 
Ohio is facing an epidemic of opioid abuse and its tragic consequences of fatal overdose.  
Greater recognition of the importance of pain management and the under-treatment 
of pain has led to a dramatic increase in numbers of prescriptions for opioid analgesics.  
Simultaneously, abuse of these drugs has risen.90  This correlation has left many physicians 
struggling with the best ways to ensure that patients get needed pain relief while 
preventing abuse of opioids.91  A solution to these issues will not be resolved by healthcare 
providers without concomitant understanding of the inextricable link between chronic 
pain and opioid use/misuse and abuse.
The Task Force recommends that additional education courses in chronic pain 
management and substance abuse be developed for healthcare professionals.  Specifically, 
the Task Force recommends: 
•	 Developing	a	holistic	pain	course	for	prescribers	developed	through	the	State	
Medical Board’s Pain Panel.  Respective professional boards and associations should 
help promote completion of this course as appropriate.
•	 Establishing	professional	medical	school	education	requirements	in	the	field	of	
substance abuse and treatment for medical professionals.  
•	 Identifying	and/or	creating	as	needed	an	online,	multi-disciplinary	toolkit	for	a	variety	
of professions that would enable easy and immediate access to continuing education 
and up-to-date information regarding key aspects of prescription drug use, misuse, 
abuse and addiction.  In addition, this toolkit should include structured screening and 
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assessment tools to increase prescription drug abuse screening among health care 
professionals.  Respective professional boards and associations should help promote 
widespread use of these toolkits.
ODH, ODADAS, the Ohio Department of Education (ODE), professional licensure boards, 
and Ohio Board of Regents (BoR), partnering with the Association of American Medical 
Colleges, state medical schools, and healthcare provider organizations should work 
together to implement this recommendation.  Success will be measured by the increased 
number of courses, professional credit hours, and substance abuse education offered by 
medical schools, professional healthcare organizations and licensing boards.
incRease UtiliZation of eVidence-Based tReatMent to Meet tHe GRowinG 
need of oPioid addicted indiVidUals seeKinG HelP
The Drug Addiction Treatment Act of 2000 (DATA 2000), Title XXXV, Section 3502 of the 
Children’s Health Act of 2000, permits physicians who meet certain qualifications to treat 
opioid addiction with medications that have been specifically approved by the Food 
and Drug Administration.  Following the passage of DATA 2000, Buprenorphine-based 
schedule III narcotic medications Subutex® and Suboxone® received FDA approval for the 
treatment of opioid addiction.  Studies have shown that Buprenorphine is more effective 
than placebo and is equally as effective as moderate doses of methadone in opioid 
maintenance therapy.  According to SAMHSA, Buprenorphine enables opioid-addicted 
individuals to discontinue the misuse of opioids without experiencing withdrawal 
symptoms.92 
To increase the utilization of evidence-based treatments, the Task Force recommends 
improved cross-referrals to DATA 2000 physicians, who prescribe opioid addiction 
medication.  In achieving this goal, developing an incentive system may improve cross-
referrals between the treatment and physical health care systems.  To support this 
recommendation, ODADAS should explore the utilization of physicians that have obtained 
a waiver under DATA 2000 to administer Buprenorphine-based medicines in Ohio.  This 
would allow the Department to gain information on how many of the DATA 2000 waived 
physicians eligible to prescribe Buprenorphine-based medications are prescribing the 
medication to patients.  
The Task Force also recommends regulatory changes to enhance the availability of 
evidence-based medication assisted treatment resources.   ODADAS should consider 
clarification of the existing Ohio Administrative Code language to allow treatment 
professionals to bill for Buprenorphine-based medication under its medical somatic 
service.  
ODADAS along with SAMHSA, healthcare provider organizations, Ohio State Medical 
Board, Ohio Council of Behavioral Health and Family Services Providers, Ohio Alliance of 
Recovery Providers and Ohio County Behavioral Health Authorities, should take the lead in 
implementing these recommendations.  Evidence of success would be demonstrated by 
an increase in utilization of evidence-based medication assisted therapies and an increase 
in activities to improve referrals to DATA 2000 physicians for treatment.  
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identifY Best PRactices foR ManaGinG acUte and cHRonic non-
MaliGnant Pain, and disseMinate and PRoMote tHese PRoVen 
aPPRoacHes to PRescRiBeRs and PHaRMacists in tHe coMMUnitY
Education is the key to the effective management of pain.  As far back as 2004, there were 
approximately 931,000 adults and 231,000 children in Ohio suffering from chronic pain, 
representing both cancer-related and non-malignant severe chronic pain.93  The cost of 
loss of productivity due to pain is estimated at $61.2 billion annually and when medical 
costs are added in, the annual cost of pain is upwards of $120 billion.94
The medications often used to treat pain can be abused, misused and illegally sold.  Most 
physicians are under-trained in pain management and many are unaware that different 
types of pain are responsive to a different type of pain medication, with opioids not always 
being the best choice.  In addition, many patients who present with pain often have 
genetic or psychosocial predisposition to addiction.  If more physicians can identify these 
issues, and are knowledgeable about alternative medications, they will be less likely to 
prescribe opioids and other addicting drugs for at-risk patients.
The Task Force acknowledges that many challenges exist in implementing this 
recommendation.  In addition to identifying best practices and ensuring they are 
consistently used in the community, physician time and access to continuing medical 
education hours can be difficult to obtain and state professional organizations may be 
hesitant to mandate education for pain when state mandates on education have not 
previously been required.  Medical schools may also be hesitant to allot additional hours 
of training for pain management when curriculums are already crowded with other 
required subjects.  To combat these challenges, the Task Force recommends that the state 
first identify best practices and have them approved by the State Medical Board of Ohio.  
Following approval, professional healthcare schools and provider organizations should be 
encouraged to disseminate and promote these approaches to students and professionals.
The lead agencies for implementing this recommendation should be the State Medical 
Board of Ohio, other professional licensing boards, healthcare provider organizations, and 
the Association of American Medical Colleges, partnering with and state medical schools, 
and the Ohio Pain Initiative.  Success will be measured by an increased knowledge base of 
a variety of medical professionals on best practices for the treatment of acute and chronic 
non-malignant pain.  Likewise, the presence of more continuing medical education credits 
and events offered on pain management throughout the year for healthcare professionals 
could indicate the effectiveness of this recommendation.
Regulatory  Recommendations 
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 REgULATORY  RECOMMENDATIONS 
The Task Force Regulatory Work Group was given the opportunity to develop 
recommendations for regulatory/legislative changes that could work to potentially 
curb Ohio’s prescription drug abuse epidemic.  The Work Group was chaired by Ernest 
E.  Boyd, R.Ph.  CAE, Executive Director of the Ohio Pharmacists Association and J. Craig 
Strafford, MD, MPH served as the vice chair representing the State Medical Board of Ohio.   
Membership was diverse and included representation from public health, medicine, pain 
management, pharmacy, nursing, behavioral health/substance abuse treatment, law 
and law enforcement.  ODH was the lead agency for the group and a facilitator from DAS 
assisted during each of the meetings.




medication (i.e.  revision of standards of practice for prescribers).
•	 Identify	options	for	increasing	the	number	of	prescribers	registered	with	the	OARRS,	
Ohio’s prescription monitoring database maintained by the BoP.
•	 Support	work	of	the	BoP	in	collaborating	with	other	states	to	link	prescription	drug	
misuse/abuse and unintentional overdose prevention.
•	 Identify	other	regulatory	strategies	to	deal	with	the	issue.
The Work Group met five times for a total of 14 hours, over the months of July, August 
and September 2010.  Members were asked to initially consider the Poison Action Group 
policy/legislative recommendations and the first Task Force report recommendations in 
small work groups.  From these recommendations, members narrowed down to a core list 
of regulatory topics for further consideration and discussion.   Presentations were made at 
the members’ request on H.B. 547 (pain clinic licensure), OARRS and physician dispensing 
of controlled substances.   Members were asked to submit specific recommendations to 
the Task Force for further consideration.  Final recommendations presented herein were 
determined after discussion with the Task Force and through a consensus-based decision-
making process.  
eXaMine tHe ReGUlation of PRescRiBeR disPensinG of contRolled 
sUBstances
Reports have shown that some pain clinics essentially operate as “pill mills” or quasi-
pharmacies by dispensing drugs that have the highest potential for abuse and diversion 
for street use with only cursory or limited medical evaluations.  This is often done as 
a direct result of pharmacists refusing to fill prescriptions from suspicious and known 
intentional over-prescribers.  It is also recognized that direct dispensing by prescribers 
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of controlled substances is not submitted to the State of Ohio’s prescription monitoring 
system, OARRS.  In 2009, Ohio prescribers dispensed prescription opioids at a much higher 
rate than neighboring states (Figure 12 and 13).
The Task Force recommends stakeholders examine regulation of in-office dispensing of 
controlled substances.  Regulations should allow for the appropriate administration of 
medications in the prescriber’s practice and permit a reasonable amount of medication 
for patients in emergency situations.  Florida has enacted legislation that would prohibit 
registered pain clinics from dispensing more than a 72-hour supply of a controlled 
substance for any patient who pays for the medication with cash, check or credit card.97   
The development of standards for in-office dispensing will eliminate the profit-motivation 
of dispensing controlled substances, allow for increased professional scrutiny by 
pharmacists and increase the likelihood that an OARRS check will be performed.
The Ohio General Assembly should partner with pain management specialists, 
healthcare provider organizations, and professional licensing boards to implement this 
recommendation.  These parties should be cognizant that regulation must be developed 
in such a way as to not impede legitimate operations of medical facilities and ensure 
the delivery of legitimate and necessary care.  If implemented, data on the purchase of 
controlled substances by prescribers is available from the DEA98 and can be utilized by 
regulatory authorities to determine the success of dispensing standards.  
RedesiGn of tHe Medicaid locK-in PRoGRaM
The Task Force recommends that ODJFS should continue its efforts to redesign the 
Medicaid lock-in program currently established in administrative rule.  The program 
would “lock-in” certain individuals to a specific physician or physician group and/or 
pharmacy for the purpose of receiving controlled substance prescription medications.  
Figure 12.  Oxycodone Purchases by Practitioners in Select States (January – December, 2009)95
ohio Pennsylvania west 
Virginia
Kentucky indiana Michigan 
dosage
Units
969,302 244,771 1,000 127,526 32,895 16,650
% 
state/total)
69.6% 17.5% .0007% 9.1% 2.3% 1.2%
Figure 13.  OxyContin Purchases by Practitioners in Select States (January – December, 2009)96
ohio Pennsylvania west 
Virginia
Kentucky indiana Michigan 
dosage
Units
97,496 7,586 0 0 1,700 180
% 
state/total)
91.1% 7.0% 0 0 1.7% 0.2%
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The program should allow patients the option to 
choose their own physician and pharmacy.  The 
purpose of the lock-in program is to maintain 
quality medical care, improve the safety of 
individuals and reduce health care costs by 
monitoring the use of controlled substance 
prescription medication dispensing patterns and 
taking action when potential misrepresentation, 
fraud, forgery, deception or abuse is identified.  
Implementation of an effective lock-in program will 
reduce the ability to doctor shop within the Ohio 
Medicaid system and may produce immediate cost 
savings to the state.  
ODJFS should partner with Medicaid managed 
care plans, pharmacies, healthcare provider 
organizations, the state’s pharmacy benefit 
manager, the Executive Medicaid Management 
Agency (EMMA), emergency room physicians, 
hospitals and other advocates to identify common 
language to ensure a uniform set of rules for all 
consumers.  Implementation of this program 
requires the establishment of uniform criteria, 
rule development, system changes, and clinical 
resources (nurses, pharmacists, physicians).  A lock-
in program lends itself to easily identifiable and 
measurable criteria.  A reduction in utilization and 
costs can be measured almost immediately upon 
enrollment.  
Currently, ODJFS is implementing a new claims 
payment system, the Medicaid Information 
Technology System (MITS).  Programming changes 
and implications will need to be assessed in the 
MITS environment.  
enaBle state aGencies and PRiVate 
enteRPRises to cReate Medication locK-in 
PRoGRaMs
There is often a need for multiple medical 
specialists or multiple pharmacy providers for any 
individual or individual medical problem.  However, 
the risk of diversion, addiction, and overdose 
increases when the intent to establish relationships 
with multiple providers is solely to increase the type 
and quantity of scheduled narcotics.  
Mary*
Both of Mary’s parents were addicted. She was first 
given a drug, OxyContin, by her alcoholic father 
who was sexually abusing her. Understandably, 
she spent as much time as possible away from 
her home and fell in with the “bad crowd” and 
began using drugs, including opioids, with them. 
Her opioid use escalated. She had a daughter 
but Children’s Services took custody of that child. 
Pregnant with a second child and with Children’s 
Services prepared to take custody of that child at 
birth, she made a decision to stop using.
Referred to counseling, she stopped “cold turkey” 
and remained abstinent for months until she 
entered the Suboxone program. The worst part of 
her use, she says was its impact on her children. “I 
didn’t know where I was 2 or 3 days at a time or 
who was taking care of my kids.” She worries about 
her daughter seeing her in withdrawal and having 
seizures, and the constant stream of people in and 
out of their home and unsavory activity that took 
place.
“We were moving around, hopping from place to 
place.” She added, “It took so much money. I would 
go around bumming money for diapers because my 
daughter was in a dirty diaper when I just spent 
$200 for drugs.” She said of her relationship with 
her children while using drugs, “I knew I loved them 
and I knew I cared about them but I didn’t care.”
Mary had friend, who was also an addict, who 
died of an overdose. The friend had prescriptions 
from 7 pain clinics with different diagnoses 
from each clinic. An autopsy, after she died of an 
overdose, showed no underlying physical diseases 
or conditions at all.
*Name has been changed; individual did not wish to 
be named. Source: Research conducted by Joe Gay, 
Executive Director, Health Recovery Services Inc.
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The Task Force recommends that enabling legislation should be enacted that would 
permit state agencies, such as the Bureau of Workers’ Compensation (BWC), and private 
enterprises that manage and reimburse for scheduled narcotics in the State of Ohio, 
to create a Medication Lock-In program.  Under this program, the agency or private 
enterprise would be able to identify member individuals who have demonstrated the 
utilization of multiple providers above a threshold for the purpose of obtaining multiple 
scheduled narcotic prescriptions or medications beyond that which is therapeutically 
necessary, and require them to select one prescriber, one distributor/retailer, or both 
for their scheduled narcotic needs, for a specified period of time.  Single prescribers and 
distributors are able to understand the comprehensive history of scheduled narcotic 
use in an individual and manage treatment to decrease the legal sources of controlled 
substances for that individual.
The Ohio General Assembly should partner with state agencies and representatives from 
the private sector that manage and reimburse for scheduled narcotics, healthcare provider 
organizations and professional licensing boards to implement this recommendation.  It 
should be noted that the restriction of free choice of providers should not be undertaken 
lightly and criteria should be developed to prevent challenges from legitimate users of 
multiple providers.  
RedUce BaRRieRs to incRease UtiliZation of eVidence-Based addiction 
tReatMent PRactices
The use of Buprenorphine is a National Institute on Drug Abuse (NIDA) evidence-based 
practice to diminish the symptoms of opioid withdrawal.  A large NIDA-sponsored, 
multisite clinical trial published in 2003 showed that “Buprenorphine and Naloxone in 
combination and Buprenorphine alone are safe and reduce the use of opiates and the 
craving for opiates among opiate-addicted persons who receive these medications in an 
office-based setting.”99
The Task Force recommends a reduction of regulatory barriers to evidence-based opioid 
treatment.  Specifically, the use of and billing for Buprenorphine-based medications,100 
which have been shown to increase successful opioid treatment efficacy.  ODADAS 
has historically interpreted the Ohio Administrative Code (OAC) in a way that prevents 
treatment organizations from being able to bill Buprenorphine as a medical somatic 
service.101  A revised interpretation could allow treatment providers who choose to use 
Buprenorphine as part of their opioid treatment regiment to bill for the management of 
the medication to Medicaid.
ODADAS should partner with ODJFS, Centers for Medicare & Medicaid Services, Ohio 
Council of Behavioral Health and Family Services Providers, Ohio Alliance of Recovery 
Providers and Ohio County Behavioral Health Authorities to draft guidance or new rules 
regarding the agency’s medical somatic service.  Recommendations on guidance or a 
new rule package could be made within a three month period.  A survey of the number 
of treatment providers that utilize Buprenorphine as an adjunct to opioid treatment 
could be used to evaluate this recommendation.  The cost of providers being able to bill 
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for Buprenorphine has not been calculated.  The stakeholder group should explore the 
funding sources available to cover the cost of this treatment.
iMPleMent cHanGes to tHe state PRescRiPtion MonitoRinG PRoGRaM
Prescription Monitoring Programs (PMPs) monitor the prescription and sale of drugs 
identified as controlled substances by the DEA.  PMPs limit traditional diversion methods 
by enabling prescribers and pharmacists to monitor patients’ prescription drug histories 
for these controlled substances and intervene when diversion and/or abuse are suspected. 
A 2002 U.S.  Government Accountability Office report102  determined that state PMPs 
improved the timeliness of law enforcement and regulatory investigations by at least 80 
percent and that the programs had deterred doctor shopping in the three states involved 
in the study.  
In Ohio, doctor shopping and prescription drug diversion are contributing factors in the 
growing prescription drug abuse and overdose epidemic.  In 2008, at least 16 percent 
of unintentional drug overdose decedents had a history of doctor shopping103  in the 
two years prior to their death.104   Increased use of the PMP by both prescribers and 
pharmacists is needed to reduce doctor shopping, diversion, insurance fraud and drug 
abuse, misuse and overdose.  
The Task Force recommends that the following changes be adopted to Ohio’s PMP, OARRS: 
Registration and Proper Use
•	 Authorize	the	BoP	and	respective	prescriber	licensing	boards	to	create	rules	
specifying when pharmacists and prescribers should register and use OARRS prior to 
prescribing controlled substances.  Allowing each professional healthcare regulatory 
board to establish their own specific rules should mitigate stated opposition to 
blanket registration/use rules.  These recommendations would allow the boards to 
establish their own rules and specify the circumstances under which a prescriber 
should check the patient’s OARRS history prior to prescribing controlled substances.  
Current law states that prescribers and pharmacists are not required to obtain 
information about a patient from OARRS.105  
Reporting and data Requirements
•	 Wholesale	distributors	who	deliver	drugs	to	terminal	distributors	should	be	required	
to report to OARRS.  Current statute requires only wholesale distributors who deliver 
drugs to prescribers to submit information to the database.  
•	 Work	with	Veteran’s	Administration	(VA)	to	encourage	VA	facilities	in	Ohio	to	report	
prescription information to OARRS.  VA facilities, per federal policy, are not required to 
submit prescription data to a state prescription monitoring program.   
•	 Change	the	ORC	so	that	information	collected	in	OARRS	shall	be	maintained	for	at	
least two years.  Only information that would identify a person will be destroyed 
after two years, unless there is a specific written request for retention of individual 
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information by law enforcement or a licensing board.  Allowing the Board of 
Pharmacy to retain de-identified data beyond two years will assist the Board in 
outlining use and abuse trends in Ohio. 
access to information and information sharing
•	 Permit	“prescriber’s	agents	registered	with	the	Board”	as	well	as	a	prescriber	to	receive	
information from OARRS.  Allowing prescriber’s agents to access OARRS should 
also reduce one of the stated barriers (i.e. time constraints) by both prescribers and 
pharmacists to use.  Criminal penalties for improperly disseminating, seeking to 
obtain, or obtaining information from OARRS should also be established.  
•	 Explore	the	feasibility	of	sharing	PMP	data	with	ODJFS/Medicaid	and	other	relevant	
state agencies (e.g., BWC) to facilitate the monitoring of client prescription drug 
histories.  Agency representatives and appropriate stakeholders should meet with the 
BoP to determine if data sharing is practical and warranted, under what conditions it 
would occur, and identify resources (financial and administrative) to develop such a 
system.  As needed, parties should recommend changes to ORC to allow for specified 
data sharing.  OARRS access will also enhance the Medicaid lock-in program because 
it will enable the State of Ohio to better identify those consumers who should be 
enrolled in the program and generally strengthen efforts to monitor the health, 
welfare, and safety of Medicaid consumers during cash transactions.
•	 Change	ORC	as	needed	to	allow	enhanced	interstate	data	sharing	in	order	to	reduce	
border jumping to obtain controlled substances.  
funding sources
•	 Explore	additional	sources	of	funding	to	increase	the	capacity	of	OARRS	in	response	
to increased demand for services.  The current system is funded by two federal grants: 
1) Bureau of Justice Assistance (administered by the U.S. Department of Justice) and 
2) NASPER (administered by the U.S. Department of Health and Human Services.
Red flag system
•	 Explore	the	feasibility	and	effectiveness	of	issuing	“red	flag”	reports	for	law	
enforcement and prescribers/pharmacists to identify individuals and prescribers who 
fall outside of normal prescription use patterns.  (Note:  The Regulatory Work Group 
members were generally supportive of this measure but emphasized caution in 
this approach as an OARRS report is not the patient’s medical record, but a listing of 
dispensed prescriptions, and quantity of medication may not be indicative of abuse.)
The Ohio General Assembly should partner with the BoP to draft legislative language 
to implement the recommended changes to the state PMP.  Once authorizing language 
is enacted, professional licensing boards and healthcare provider organizations should 
collaborate on the adoption of rules specifying when pharmacists and prescribers should 
register and use OARRS.  Registration and use of OARRS by prescribers and pharmacists as 
tracked by the BoP and the distribution of controlled substances to doctor shoppers, as 
measured through OARRS data, should be used to evaluate the proposed changes.  
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encoURaGe incReased initial and continUinG edUcation on Pain 
ManaGeMent and dRUG aBUse
Pain is one of the leading reasons people seek medical advice.106  Chronic pain prevalence 
in the adult population has been conservatively estimated at 57 percent.107  Despite the 
rapid increase in opioid prescribing, drug abuse and overdose rates, there has been no 
corresponding increase in the education of prescribers.  From 1999 to 2007, Ohio’s rate 
of opioid distribution in grams per 100,000 population increased 325 percent while the 
unintentional drug overdose death rate increased 305 percent.108  This data supports the 
need for increased education of health care providers about opioids and related issues of 
pain management and prescription drug abuse.   
The Ohio Compassionate Care Task Force final report (2004) concluded that there was 
an inadequate education and professional training in areas of pain management and 
addiction medicine.109  The report identified several barriers to quality care of chronic pain 




The Federation of State Medical Boards updated and revised its pain guidelines now called 
Model Policy for Use of Controlled Substances for the Treatment of Pain.110  They identified 
four circumstances that lead to poor pain treatment:
1. Lack of knowledge of medical standards, current research, and clinical guidelines for 
appropriate pain treatment.
2. The perception that prescribing adequate amounts of controlled substances will 
result in unnecessary scrutiny by regulatory authorities. 
3. Misunderstanding of addiction and dependence.
4. Lack of understanding of regulatory policies and processes.
The Task Force recommends increased education among health care professionals on 
issues of drug abuse, addiction and pain management should be strongly encouraged for 
both initial and continuing education.  Medical, pharmacy, nursing and other professional 
healthcare schools should incorporate these subject areas within their curricula and 
a minimum number of hours should be identified.   The Ohio State Medical Board, in 
cooperation with other appropriate professional licensing boards and healthcare provider 
associations should collaborate to identify, and/or develop as needed, continuing 
education programs to address the lack of education.  A minimum number of hours 
for continuing education on these topics should also be identified and recommended 
depending on the area of practice.  Incentives should be developed to encourage 
healthcare professionals to obtain adequate continuing education.






registration and use requirements/recommendations.
•	 Responsible	and	appropriate	opioid	prescribing	with	particular	attention	to	
education about initial doses for acute pain, long-acting or extended release opioids 
with higher risk for overdose, and use of opioids in conjunction with other prescribed 
central nervous system depressants.
•	 Chronic	pain	management	including	types	of	pain,	psychology	of	pain,	tolerance/
dependence/addiction, patient education and safety (e.g., medication contracts, drug 
screens), discussion of risks with patients, and alternative (non-opioid) treatment 
strategies.
•	 Substance	abuse	including	disease	of	addiction,	assessment/identification,	discussing	
abuse with patients, identifying and managing drug seeking behavior and referrals to 
substance abuse treatment providers.
•	 Importance	of	patient	education	and	providing	simple	instructions	regarding:
- Taking medication exactly as prescribed and the dangers of overuse/misuse, 
sharing medications, mixing medications and the warning signs of overdose.  
- Potential for physical dependence, abuse and/or addiction with prolonged use of 
prescription pain opioids.
- Safe medication storage and proper disposal of unused medication.  
The Task Force recommends the following activities for initial education in professional 
healthcare schools: 
1. Convene a curriculum committee within the school to discuss and collaborate on the 
development of curriculum to address pain management and drug abuse issues as 
listed above.
2. Collaborate with other professional schools across Ohio and other states on the 
development of the curriculum.  
3. Research course syllabi developed at other professional schools to serve as a model.   
4. Establish standards for content and recommended number of hours for specific 
topics.
5. Develop curriculum and identify appropriate professors from other disciplines as 
needed to teach or “guest lecture” on specific topic areas such as identifying and 
intervening with drug abusers and strategies for addressing drug seeking behavior.  
6. Incorporate course into overall curriculum and set completion requirements as 
appropriate.  
The Task Force recommends the following activities for continuing education of healthcare 
professionals: 
1. Convene a continuing education committee to address this topic comprised of 
appropriate licensing board and member association representatives.
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2. Establish recommended standards for content and recommended number of hours 
for continuing medication education.
3. Identify existing curricula meeting those standards and adapt as necessary for use in 
Ohio.
4. Disseminate recommendations and promote availability of courses through 
professional boards and associations to all relevant professionals with controlled 
substance prescribing authority.
5. Licensing boards and associations should develop a means of tracking course 
completion and measuring trends.
Professional licensing boards should partner with healthcare provider organizations, Ohio 
colleges of medicine and pharmacy, and representative healthcare agencies on the Task 
Force to encourage education on pain management and drug abuse among students and 
professionals.    
There will be costs associated with making these adaptations, promoting the curricula 
and/or coordinating courses through professional organizations and colleges of medicine.  
However, increased education of healthcare providers may ultimately result in cost savings 
to law enforcement, health insurers and hospital systems.  Developmental costs may be 
minimized since curricula exist locally in Ohio and in other states that can serve as a model 
or may be adapted.   
A recent study, conducted by the Geisinger Health System,111  concluded that the group 
most vulnerable to addiction has four main risk factors in common: age (being younger 
than 65); a history of depression; prior drug abuse; and use of psychiatric medications.  
Painkiller addiction rates among patients with these factors are as high as 26 percent.  
This study shows that by learning more about the patient, and assessing for these risk 
factors, which can be identified through further research, prescribers can better treat 
their patients’ pain without the potential for future drug addiction.  Initial and continuing 
education on these subjects is critical to the efficacy of assessing risk factors.
Note:
Some members of the Regulatory Work Group felt strongly that these continuing 
education recommendations should be elevated to requirements by the respective 
professional licensing boards; however, consensus could not be achieved on required 
continuing medical education.  
Public Health Recommendations 
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 pUBLIC hEALTh  RECOMMENDATIONS 
The Task Force Public Health Work Group was presented with the task of identifying public 
health strategies to address prescription opioid abuse.  The Work Group was chaired by Dr.  
Aaron Adams, Scioto County Health Commissioner and David Baker, PharmD, DABAT, the 
Managing Director of the Central Ohio Poison Center served as the vice-chair.  The Work 
Group was comprised of 26 members representing a wide range of disciplines from across 
the state including public health departments, alcohol and drug treatment programs, 
alcohol and drug prevention programs, veterans services, two colleges of pharmacy, 
mental health boards, health care professional associations, advocacy organizations, 
community coalitions and state agencies and licensing boards.  The work group was 
staffed by the ODH and a facilitator from the ODJFS ) assisted with each of the meetings.





prescription drug misuse/abuse and unintentional overdose prevention. 
•	 Identify	other	public	health	strategies	to	deal	with	the	issue.	
The Work Group held four meetings in the Columbus area between July and September 
2010.  The group’s Recommendations were identified through large group discussion 
and small group work and final decisions were achieved through consensus.  Five 
recommendations were submitted to the Task Force for further consideration.  Final 
recommendations presented herein were determined after discussion with the Task Force 
and through a consensus-based decision-making process.  
estaBlisH new and sUPPoRt eXistinG local coalitions/tasK foRces to
addRess tHe PReVention of PRescRiPtion oPioid MisUse, aBUse and 
oVeRdose
Local coalitions are a key element in combating prescription opioid abuse, as they can 
provide the opportunity for collaboration among entities that are concerned with this 
problem, but may not typically interact with one another.  Coalitions are also important 
because members are able to combine their resources and voices and become more 
powerful than if each one was to act alone.  This can broaden the conversation and focus 
to more comprehensively address the problem.  Coalitions can serve as a mechanism 
for local capacity building and an ongoing base for change.  Coalitions with diverse 
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membership expand the number of people who 
are educated about the issue and can serve as 
advocates.
The Task Force recommends the establishment of 
new and the support of existing local coalitions to 
address prevention of prescription opioid misuse, 
abuse and overdose.  Many effective models of 
coalition development are available for use by local 
organizations including the Community Anti-Drug 
Coalition of America, the Public Health Model 
promoted by the Centers for Disease Control and 
Prevention, and the Incident Command Model 
used by health departments in responding to 
public health emergencies. However, activities 
implemented by coalitions should be community 
specific and based on local data and demographics.  
Coalitions addressing alcohol and drug addiction 
already exist in many counties in Ohio and should 
be encouraged to expand their focus to include 
prescription opioid abuse, while new coalitions 
must be developed in areas without existing 
coalitions.  Coalition activities should be designed 
to reach many different populations in a variety of 
settings to provide education and opportunities for 
taking action.
The Ohio Drug-Free Action Alliance (DFAA), which 
houses the Center for Coalition Excellence, should 
implement this recommendation.  The DFAA 
should also provide coordination and technical 
assistance.  In addition, the Task Force recommends 
that a coalition development toolkit be created 
and disseminated.  An internet site should also be 
established to house all coalition related activities 
in the state.  The DFAA should work with the ODH 
and the ODADAS to coordinate their efforts with 
those already underway.  
There are a variety of potential funding sources to 
assist with coalition development that should be 
explored.  These sources include coalition mini-
grants from the DFAA, federal grants, support from 
pharmaceutical companies, asset forfeiture funds 
from prosecuted drug cases, Attorney General 
Settlement funds, and the Drug-Free Communities 
grant from the Office on National Drug Control 
Policy.
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“My first child was not interested in drugs but 
I found out later that she was in a minority.  My 
son didn’t escape so innocently. He suffered a 
significant football injury during a playoff game 
that changed his life plans. I do believe this was 
his entry into serous pain killer use.   
My family was not ready for what would follow 
but as soon as I found out seven years ago I 
knew we were in big trouble.  Being a healthcare 
professional, for over 25 years by that time, I knew 
if opiate pain killers were involved, addiction 
would be a severe problem.  Fortunately he is 
still here and has battled back to be better with 
treatment, time, and maturity.
Of course being an angry mother I investigated 
the problem thoroughly and what I found was 
shocking.  The number of young people involved 
in this was not believable at first. I can honestly 
say that every family in the area has been affected 
by this problem in some way. The problem reaches 
across economic classes.  
The abuse of opiates eventually led to an increased 
number of deaths—several young people 
included. Crime escalated after oxy hit the streets, 
the welfare of children suffered and many kids 
were transferred to the care of their grandparents 
and others through children services.  
My co-worker said that ”drugs have crippled our 
area.” The counties hardest hit by this epidemic 
have decreased in appearance, poverty has 
increased and kids are suffering from this very 
serious problem.  Our community has received a lot 
of negative attention, people have chosen to move 
out of the area, the school enrollment is down and 
the financial impact on the school district is huge. 
I think there is even a question if the school system 
will remain intact.”
Source: Research conducted by Joe Gay, Executive 
Director, Health Recovery Services Inc.
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fUnd and iMPleMent social MaRKetinG (PUBlic awaReness and oUtReacH) 
caMPaiGns to cReate awaReness aBoUt PRescRiPtion oPioid MisUse, aBUse 
and oVeRdose to cHanGe PUBlic PeRcePtion and inflUence BeHaVioR
According to the Institute for Safe Medication Practices, half of the prescriptions taken 
each year in the United States are used improperly.  In addition, a 2005 study by SAMHSA 
found that 53 percent of individuals ages 18-25 obtained free prescription pain relievers 
from relatives or friends for nonmedical use in the past year.  The study also showed that 
10.6 percent bought the pain reliever from a relative or friend.112  These, and other studies, 
document the high rates of fatal unintentional drug overdose and point to a critical need 
for more public awareness about the proper use of prescription pain relievers.  
The Task Force recommends ODH in conjunction with ODADAS, and other state and local 
partners, lead an effort to raise public awareness about Ohio’s prescription drug abuse 
epidemic.  ODH should explore and identify potential funding sources to expand current 
social marketing efforts and initiate new efforts focused on at-risk populations.
Social marketing campaigns can assist with dispelling misconceptions and emphasizing 
the potential dangers if pain relievers are not taken properly.  The goal of a social 
marketing campaign should be a reduction in the devastating toll that this problem takes 
on individuals, families and communities including a reduction in hospitalizations, family 
instability, incarceration, economic instability and the need for treatment.
The campaign should leverage all available outlets, including, but, not limited to, 
traditional media (radio, TV, newspapers, bill boards, bus signs, etc.), social media 
(Facebook, Twitter, etc.), community events, trade publications, and electronic newsletters 
of professional associations.  The Task Force recommends that specific and distinct 
messages should be used to effectively reach various populations such as middle-aged 
adults (males and females), youth, those already addicted, children and parents.  Messages 
should be specific to preventing first use, addiction and death and include information 
about the potential for a person misusing or addicted to prescription opioids to transition 
to heroin due to similar properties between the two.
For future campaigns, ODH can use the resources developed for the current Prescription 
for Prevention Campaign.  However, funding will be needed for social marketing 
campaigns to be effective.  Potential funding sources include corporate grants, federal 
grants, and foundation grants.  In addition, public-private partnerships with local media 
outlets for Public Service Announcements should be explored.
PRoVide edUcation to incRease awaReness, KnowledGe and ResoURces 
Related to tHe RisKs of PRescRiPtion Pain RelieVeR MisUse, aBUse and 
oVeRdose
There is a public perception that prescription opioids are safe because they are prescribed 
by a healthcare provider.  However, misuse of these drugs, including sharing with others, 
taking more than prescribed, and/or combining them with other drugs and/or alcohol can 
be lethal.  In 2007, 70 percent of all unintentional drug poisoning deaths in Ohio involved 
a prescription opioid or “other/unspecified” (i.e. multiple drugs).  In 2008, there were 1,473 
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fatal unintentional drug overdoses, a 350 percent increase from 327 such deaths in 1999.113 
To effectively combat this growing epidemic, comprehensive education is needed in every 
sector of society.  
The Task Force recommends that comprehensive, population specific and age appropriate 
education take place throughout the state, including education to intervene with those 
already addicted to prescription opioids.  In some cases, information about this problem 
can be included in existing efforts such as alcohol and drug prevention programs already 
in schools.  However, for this recommendation to be successful, a comprehensive, 
coordinated and consistent state primary prevention strategy must be identified and a 
“train the trainer” approach should be used.
These educational efforts, including the use of model programs and tool kits, should 
take place at all levels and in multiple settings (i.e.  with students, parents, those in the 
work force, health care providers, in health care settings, with law enforcement, with faith 
institutions and with policy makers.)  The focus should be on the prevention of abuse, 
addiction and death.  In addition, information should be included about the potential 
for transitioning to heroin abuse and addiction if a person is misusing or addicted to 
prescription opioids.
This effort should be led by a committee of state agencies/boards, to specifically include, 
ODE, ODH, BWC, ODADAS, the Board of Regents, the Ohio Attorney General’s Office-
Electronic Ohio Peace Officers Training Academy (E-OPOTA), the Ohio Department of 
Public Safety (Office of Criminal Justice Services), ODJFS, the Department of Veterans 
Affairs,  and professional licensing boards.
These state agencies should be assisted in the effort by other state partners such as 
healthcare provider organizations, citizen action groups, business associations and 
colleges and universities across the state.  Local organizations and agencies are also 
a critical part of this educational effort and should be engaged as partners.  Potential 
sources of funding to support these efforts include grants from pharmaceutical companies 
and using a portion of the money from drug forfeitures.
facilitate tHe PRoPeR disPosal of PRescRiPtion Medications
Leftover or unused medications in homes or other settings can be an easy access source 
for those seeking to obtain prescription pain opioids.  Programs are needed to decrease 
the availability and accessibility of unused prescription drugs in the home and increase 
the number of prescription medications that are stored properly and disposed of correctly. 
Currently, based on the experience of members of the Task Force’s Public Health Work 
Group, who represent communities around the state, there is a lack of coordination 
among groups and individuals holding drug disposal events.  In addition, there is a lack of 
knowledge and/or resources to coordinate and implement drug take-back events.  
The Task Force recommends that Drug Disposal Day Guidelines (DDDG) be developed 
by ODH.  Once complete the DDDG should be distributed by Task Force member 
organizations through their networks.  In addition, he DDDG should be posted on the web 
sites of these agencies/organizations.
65
Drug disposal events should be implemented by the local coalitions working in 
conjunction with local law enforcement agencies.  In addition, direction and guidelines 
should be provided to communities and/or groups interested in holding a drop-off event.  
Educational materials specific to proper disposal should be disseminated similar to
www.smarxtdisposal.net.  In addition, data should be collected related to the drop-off 
event to help plan future events and to document and share the value of the event.
Costs for these events include printing for event flyers, newspaper, TV and radio ads, 
permits, disposal containers, and signage at the event.  Potential sources of funding 
include community business partners, hospitals, colleges, universities, student 
organizations, local civic or business associations, and local ADAMH boards.  
iMPRoVe and cooRdinate data collection Related to PRescRiPtion Pain 
RelieVeR MisUse, aBUse and oVeRdose
Improved and coordinated data collection is needed in order to provide an increased 
understanding of the extent of the problem and to identify patterns of misuse and 
abuse of the drugs involved.  Improved data will document the need for prevention 
and treatment services and will assist decision makers as they develop appropriate 
interventions.  In addition, this data will help to measure the impact and outcomes of the 
initiatives of the Task Force and the state of Ohio.
The Task Force recommends that the ODH, working with the Ohio Injury Prevention 
Partnership (OIPP), identify and convene data owners collecting data relevant to this 
problem.  ODH should develop a data committee to create a comprehensive plan to 
address data collection and data linkage.  The development of this plan should include 
consideration of: actions needed to make prescription drug overdose a reportable 
condition; standardized data elements for collection; a review of trend data; a method for 
regularly updating trend data; a review of current surveys and data collection methods; 
identification of gaps in knowledge and information gathered from these surveys and 
data collection methods; questions for the surveys to address the identified gaps; and, 
recommendations to improve data collection methods.
Further, it is recommended that this committee support the work of the BoP in 
collaborating with other states to:
•	 Link	prescription	monitoring	systems.	
•	 Review	the	results	from	the	Poison	Death	Review	Committees	(PDR)	established	in	
Scioto and Montgomery Counties as part of ODH funded pilot projects.
•	 Make	recommendations	regarding	the	replication	of	the	PDRs	in	other	parts	of	the	
state (if the results are found to be positive). 
•	 Work	with	the	Ohio	Coroners	Association	to	increase	the	capacity	of	coroners	to	
improve data collection (particularly toxicology reports related to prescription drug 
misuse, abuse and overdose). 
•	 Explore	the	feasibility	of	statutory	and	rule	changes	to	require	data	submission.
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Potential sources of funding include implementing an “add-on” to criminal fines, applying 
for federal grants and, assessing penalties and fines on pain management clinics for non-
compliance and failure to meet appropriate standards of care.
Task Force Progress
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 TASK FORCE pROgRESS 
The Task Force’s initial report, in addition to charging the Task Force Work Groups to 
develop recommendations, included recommendations encouraging support for 
community education and awareness efforts.  Several of these efforts have already begun 
to take place.  
Two unprecedented prescription drug take back programs will take place this year.  On 
September 25, the DEA spearheaded its first ever nationwide Prescription Drug Take Back 
Day, in cooperation with government, community, public health, and law enforcement 
partners around the country, including many in Ohio.  To encourage Ohioans to properly 
dispose of unused prescription medication, Governor Ted Strickland designated 
September 25 as “Ohio Prescription Drug Take-Back Day”.  Additionally, the 2010 American 
Medicine Chest Challenge, hosted by The Partnership for a Drug-Free New Jersey, is also 
aimed at collecting unused prescription medications.  This is the first year the American 
Medicine Chest Challenge is being launched on a national scale and communities, in Ohio 
and across the nation, will sponsor drug take back programs on November 13, 2010.  
In an effort to assist law enforcement agencies, on June 14, 2010, the Ohio Office of 
Criminal Justice Services (OCJS), a division of the Ohio Department of Public Safety, 
announced the Ohio Prescription Drug Grant.  The grant provided funding to defray 
expenses that a prescription drug investigation incurs in performing its functions related 
to the enforcement of the states prescription drug laws and other state laws related to 
illegal prescription drug activity.  The funds, totaling $250,000 with a maximum of $15,000 
per application, can be used for overtime costs of case investigators, equipment necessary 
to complete the investigation and costs for prosecuting the case.  
In an effort to prevent unintentional prescription drug overdoses, ODH is funding an 
outreach campaign titled Prescription for Prevention: Stop the Epidemic.  The campaign 
focuses on enhancing awareness and creating behavior changes in counties with some of 
the highest rates of unintentional prescription drug overdose.  The counties with coalitions 
receiving direct support from ODH are: Adams, Cuyahoga, Jackson, Ross and Vinton.   The 
campaign materials are available for download at www.P4POhio.org.  
In addition to these efforts, the Task Force Chair and Vice-Chair sent a letter to health care 
professional organizations asking for support in raising awareness about this issue in 
upcoming meetings, conferences, courses, grand rounds and newsletters.  Many of the 
professional organizations have responded positively to this letter and pledged to assist 
the Task Force is raising awareness about Ohio’s prescription drug abuse epidemic.  The 
response letters can be found in the appendix of this report.
Appendix
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Matthew A. Fettman, R.Ph.   
Prescription drug abuse is being described as epi-
demic in Ohio. Governor Strickland signed an ex-
ecutive order in April that has established the Ohio 
Prescription Drug Abuse Task Force (OPDATF) to 
study the issues and return a comprehensive plan 
of action. OPA Executive Director Ernie Boyd has 
been appointed to the Task Force. Work groups 
for the Task Force have been formed and meet-
ings have begun. The Work Groups include: Treat-
ment Work Group, Public Health Work Group, 
Regulatory Work Group, and Law 
Enforcement Work Group. Several 
OPA members and staff have been 
appointed to the work groups.
How did the problem get to the 
point where it can be described as 
epidemic? Controlled substances 
are not supposed to be easily ob-
tained. That being said, how does someone obtain 
access to quantities large enough to maintain their 
habit? Doctor shopping, frequent emergency room 
visits, and buying from drug traffickers are prob-
ably the most common means of acquiring the 
medications.
The Ohio Automated Rx Reporting System 
(OARRS), Ohio’s prescription monitoring program, 
is a tool available for pharmacists, prescribers, and 
law enforcement officials to identify individuals 
who are attempting to obtain controlled substanc-
es. Governor Strickland’s press release announcing 
the OPDATF stated “…all pharmacists report into 
this system, but only one in five use the system 
when filling prescriptions.” This is a statistic we 
can improve. Next time you speak with a colleague 
to transfer a prescription, ask if he/she uses the 
OARRS program. Be sure to explain how helpful 
it is when a questionable controlled substance pre-
scription crosses the counter.
The Board of Pharmacy stresses the word “tool” 
when describing OARRS because the information 
gathered from an OARRS report should aid in 
making a judgment in deciding whether or not to 
fill a prescription. The data produced in an OARRS 
report must be carefully considered.
OPA published a home study jurisprudence 
program in the June 2009 issue of the Ohio Phar-
macist journal, “OARRS:  Ohio’s Prescription 
Monitoring Program.” The lesson was a good re-
view of the inception, implementation, and current 
outcomes of OARRS, as well as future plans. If you 
haven’t already read it, do so now. 
You can even get Ohio jurispru-
dence credit for it. OPA members 
can access a PDF of the lesson at 
www.ohiopharmacists.org (Educa-
tion/Law and Home Study CE). 
The lesson expires May 28, 2011. 
For more information on OARRS, 
visit www.ohiopmp.gov.
In addition, OARRS is also a tool used in 
identifying prescribers and pharmacists who are 
not practicing responsibly. The drugs are reaching 
the street somehow. Governor Strickland emphati-
cally stated, “…And so to all the pill mills out there 
making a profit by selling a poison, let me be clear. 
We’re coming for you. What you do is illegal and 
immoral, and we will fight you with everything we 
have.”
“Pain management is a legitimate medical 
concern and in no way will we interfere with neces-
sary medical responses to chronic pain. But there 
is no place for physicians or pharmacists who are 
not meeting any acceptable standard of care and 
are apparently dispensing prescriptions, not as a 
means to help a patient, but as a means to enrich 
themselves.”
We can help end the epidemic. And when you 
recommend utilization of OARRS to a colleague, 
suggest they join OPA also!
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